Reducing the Impact of Influenza Viral Load on Patient and Community Health - a podcast by ReachMD

CME credits: 0.25

Valid until: 30-06-2021

Claim your CME credit at https://reachmd.com/programs/cme/reducing-the-impact-of-influenza-viral-load-on-patient-and-community-health/10833/

The newer option that’s available to treat the flu is not a neuraminidase inhibitor, but an endonuclease inhibitor, and both work differently in their approach to reducing the viral load and the viral shedding of the flu virus. This activity will discuss how we can integrate these options into personalized treatment plans and the impact of influenza on at-risk and high-risk individuals.

Since the launch of the activity, the US FDA has approved a new indication for baloxavir marboxil to include the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours, who are otherwise healthy, or who are at high risk of developing flu-related complications.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD